par Desmet, Agnès 
;Van Schil, Paul;Van Houtte, Paul
Référence Revue des Maladies Respiratoires Actualites, 10, 3, page (326-331)
Publication Publié, 2018-10
;Van Schil, Paul;Van Houtte, Paul Référence Revue des Maladies Respiratoires Actualites, 10, 3, page (326-331)
Publication Publié, 2018-10
Article révisé par les pairs
| Résumé : | Oligometastatic disease has become a highly controversial topic with treatment options ranging from conservative therapy to more agressive modalities with the principal aim to control the primary tumour and distant metastatic sites. There is a clear relationship with the current progress in systemic therapies, but also specific advances in surgical and radiation techniques. Most available data come from retrospective studies with their inherent bias but two smaller randomised trials have recently been published. Precise patient selection for such an agressive treatment remains a major challenge. There is a risk of overtreatment with its associated complications and reduction of quality of life. On the other hand, long-term survival has been described in a well-selected population. |
